Reteplase plus abciximab and reteplase alone led to similar 30-day mortality rates in acute MI.

P a t i e n t s 16 588 patients who were ≥ 18 years of age (mean age 61 y, 75% men) and had continuous symptoms of chest discomfort for ≥ 30 minutes and < 6 hours from onset to the time of randomization, and electrocardiographic criteria of ST-elevation MI or new left bundle-branch block. Exclusion criteria were planned catheter-based reperfusion; active bleeding or a noncompressible vascular puncture site; systolic and diastolic blood pressures > 180 mm Hg and 110 mm Hg, respectively; warfarin therapy; stroke in the previous 2 years; weight > 120 kg; or platelet count < 100 000 cells/μL. Follow-up was 98%.